skip to Main Content

Dr. O’Reilly on Immunotherapy in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center, discusses the role of immunotherapy in the treatment of patients with pancreatic cancer.

The treatment landscape of pancreatic cancer is an area in flux, says O’Reilly. Pancreatic cancer is traditionally considered to be an immune-resistant disease. There is a lack of effector T cells, an abundance of myeloid-derived suppressor T cells, and a dearth of key immune effector and regulatory cells. Read more . . .

Back To Top